Daxor Corp. (DXR) Reports Publication of New Data that Demonstrates Clinical Utility with Daxor’s Blood Volume Analyzer (BVA-100) in Critical Care

February 4, 2021 8:49 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Daxor Corporation (NYSE: DXR) the global leader in blood volume measurement technology, today announces new data from the University of Hawaii John A. Burns School of Medicine showing the BVA-100 blood test accurately and uniquely reflects blood volume status after massive blood transfusion, a key metric for this procedure, while traditional clinical metrics fail in 80% of the cases analyzed.

The aim of the study titled “A Quantitative Analysis of Clinical End Points of Resuscitation After Massive Blood Transfusion,” was to perform a comparative analysis of blood volume status following massive transfusion protocols (MTP), both clinically and quantitatively, to determine if endpoints of resuscitation were adequately achieved utilizing the BVA-100 blood test. Jonathan Feldschuh, Daxor's Chief Scientific Officer stated "A key goal of MTP is to save critically ill patients suffering severe blood loss by transfusing them to euvolemia -- when care teams do not give optimal transfusions there can be significant negative and sometimes fatal outcomes."

Data presented revealed that only 20% of the patients in this study were euvolemic (optimal blood volume), with 24% demonstrating hypovolemia (too little blood volume), despite meeting traditional clinical surrogates indicative of euvolemia. Whitney Carlton, M.D., lead investigator concluded, “Traditional endpoints of resuscitation after implementation of MTP may not accurately reflect true blood volume.”

“This data is concordant with a wide body of published studies showing that indirect measures offer low clinical utility as indicators of true intravascular volume status,” said Michael Feldschuh, President and CEO of Daxor Corporation. “The BVA-100 blood test provides a simple and accurate means to directly measure blood volume and composition ensuring that MTP is effective and accurate. We are excited that our diagnostic is being used to support the ongoing research in the area of critical care.”

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Related Entities